Trial Profile
Mesylate tablets of apatinib as first-line treatment of metastatic soft tissue sarcoma, randomized, crossover, multi center clinical study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 02 Aug 2018 New trial record